Quell Therapeutics to Participate at Upcoming Healthcare Investor Conferences in 2024

Quell Therapeutics to Participate at Upcoming Healthcare Investor Conferences in 2024

6th November 2024

Quell Therapeutics to Present Promising Data from Autologous and Allogenic CAR-Treg Progra...

Quell Therapeutics to Present Promising Data from Autologous and Allogenic CAR-Treg Programs at Upco...

22nd October 2024

Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair...

Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Bo...

10th July 2024

Quell Therapeutics Advances QEL-001, its Multi-modular Engineered CAR- Treg Cell Therapy, ...

Quell Therapeutics Advances QEL-001, its Multi-modular Engineered CAR- Treg Cell Therapy, into Effic...

5th June 2024

Quell Therapeutics Highlights Clinical Potential of QEL-001 and its Multi-Modular Treg Cel...

Quell Therapeutics Highlights Clinical Potential of QEL-001 and its Multi-Modular Treg Cell Therapy ...

2nd May 2024

Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with Astr...

Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to...

9th June 2023

Quell Therapeutics to Present at Upcoming Investor Conferences in 2022

Quell Therapeutics to Present at Upcoming Investor Conferences in 2022

22nd November 2022

Quell Therapeutics Appoints Luke Devey, BMBCh, Ph.D. as Chief Medical Officer

Quell Therapeutics Appoints Luke Devey, BMBCh, Ph.D. as Chief Medical Officer

21st November 2022

Quell Therapeutics and Cellistic™ enter a strategic collaboration to develop an iPSC-deriv...

Quell Therapeutics and Cellistic™ enter a strategic collaboration to develop an iPSC-derived allogen...

27th April 2022

Quell Therapeutics Announces Presentation at Oppenheimer’s 32nd Annual Healthcare Conferen...

Quell Therapeutics Announces Presentation at Oppenheimer’s 32nd Annual Healthcare Conference

10th March 2022

Quell Therapeutics Announces Presentation at the 40th Annual J.P. Morgan Healthcare Confer...

Quell Therapeutics Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference

6th January 2022

Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its...

Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneerin...

29th November 2021

Quell Therapeutics Announces Participation in Upcoming Investor Conferences

Quell Therapeutics Announces Participation in Upcoming Investor Conferences

22nd November 2021

Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular...

Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineere...

27th October 2021

Quell Therapeutics Presents New Data Demonstrating the Ability of its Proprietary Phenotyp...

Quell Therapeutics Presents New Data Demonstrating the Ability of its Proprietary Phenotype Lock Tec...

19th October 2021

Quell Therapeutics Significantly Expands Clinical Manufacturing Capacity for its Engineere...

Quell Therapeutics Significantly Expands Clinical Manufacturing Capacity for its Engineered Treg Cel...

23rd September 2021

Quell Therapeutics to Present at the 2021 Wedbush Pacgrow Healthcare Virtual Conference

Quell Therapeutics to Present at the 2021 Wedbush Pacgrow Healthcare Virtual Conference

4th August 2021

Quell Therapeutics Appoints Dominik Hartl, M.D., as Chief Medical Officer

Quell Therapeutics Appoints Dominik Hartl, M.D., as Chief Medical Officer

29th July 2021

Quell Therapeutics Appoints Tracey Lodie, Ph.D., as Chief Scientific Officer

Quell Therapeutics Appoints Tracey Lodie, Ph.D., as Chief Scientific Officer

29th July 2021

BioCentury – Quell: tweaking Tregs for persistence, potency and stability

BioCentury – Quell: tweaking Tregs for persistence, potency and stability

6th April 2021

Quell Therapeutics Expands Series A Financing to $84 Million

Quell Therapeutics Expands Series A Financing to $84 Million

11th February 2021

Quell Therapeutics Enters a Collaborative Research Agreement with the University of Sheffi...

Quell Therapeutics Enters a Collaborative Research Agreement with the University of Sheffield

26th October 2020

Quell Therapeutics strengthens its Board with the appointments of Dr Dhaval Patel and Sir ...

Quell Therapeutics strengthens its Board with the appointments of Dr Dhaval Patel and Sir Robert Lec...

11th June 2020

Quell Therapeutics Enters a Collaborative Research Agreement with the Hannover Medical Sch...

Quell Therapeutics Enters a Collaborative Research Agreement with the Hannover Medical School

8th April 2020

T regs are back – promising to do for autoimmunity what CAR Ts have done in cancer

T regs are back – promising to do for autoimmunity what CAR Ts have done in cancer

24th February 2020

Quell Therapeutics named a “Fierce 15“ Company by FierceBiotech

Quell Therapeutics named a “Fierce 15“ Company by FierceBiotech

23rd September 2019

Quell Therapeutics, founded by Syncona Ltd, appoints Chief Executive

Quell Therapeutics, founded by Syncona Ltd, appoints Chief Executive

13th June 2019